<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753467</url>
  </required_header>
  <id_info>
    <org_study_id>TONG-HBV-0801</org_study_id>
    <nct_id>NCT00753467</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B</brief_title>
  <official_title>Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huntington Medical Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Huntington Medical Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, prospective, two part study evaluating IFN-γ 1b at a dose of 200μg by&#xD;
      subcutaneous injection every day either alone or in combination with Adefovir dipivoxil or&#xD;
      Adefovir dipivoxil alone at a dose of 10mg QD in patients with chronic Hepatitis B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After signing the informed consent potential patients will undergo a screening medical&#xD;
      history, physical examination, and laboratory tests.&#xD;
&#xD;
      The study will consist of two parts:&#xD;
&#xD;
        -  Part A: IFN-γ 1b monotherapy&#xD;
&#xD;
        -  Part B: IFN-γ 1b combination therapy with Adefovir dipivoxil or Adefovir dipivoxil&#xD;
           monotherapy&#xD;
&#xD;
      Patients will be enrolled sequentially into to one of three treatment groups. In Part A, ten&#xD;
      patients will be enrolled and will receive IFN-γ 1b 200μg, administered every day by&#xD;
      subcutaneous injection for 4 weeks. If HBV DNA is reduced by ≥ 1 log10 copies/ mL in ≥ 30% of&#xD;
      patients the protocol will proceed to Part B.&#xD;
&#xD;
      In Part B, twenty patients will be enrolled into two cohorts (total of 10 for each cohort)&#xD;
      and treated for four weeks. The two cohorts will be administered:&#xD;
&#xD;
        -  IFN-γ 1b 200μg, administered every day combination therapy with Adefovir dipivoxil (10mg&#xD;
           QD) or&#xD;
&#xD;
        -  Adefovir dipivoxil (10mg QD) alone&#xD;
&#xD;
      On the initial study visit, patients will be given instruction on self injection of IFN-γ 1b&#xD;
      (if applicable). Patients will be monitored for safety, tolerability, HBV DNA, clinical&#xD;
      chemistries including a standard panel of liver tests and hematologies throughout the study&#xD;
      and for the two week post-treatment observation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the safety and tolerability of IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in serum HBV DNA concentrations following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in liver tests and hematology following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir dipivoxil monotherapy (10 mg QD) 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-γ 1b (Actimmune)</intervention_name>
    <description>IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Interferon gamma</other_name>
    <other_name>Actimmune</other_name>
    <other_name>Immune Interferon</other_name>
    <other_name>IFN-gamma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
    <description>Adefovir dipivoxil: 1 tablet of 10mg given orally QD</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-γ 1b and Adefovir dipivoxil combination</intervention_name>
    <description>IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Actimmune</other_name>
    <other_name>Interferon gamma</other_name>
    <other_name>IFN gamma</other_name>
    <other_name>Immune Interferon</other_name>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must fulfill all of the following criteria to be eligible for enrollment into the&#xD;
        study:&#xD;
&#xD;
          1. Men or women age 18 to 75 years&#xD;
&#xD;
          2. Chronic hepatitis B infection based on a history of positive anti-HBsAg and positive&#xD;
             for HBV DNA and with or without elevations in liver tests (test to be repeated on&#xD;
             screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following will be excluded from randomization:&#xD;
&#xD;
          1. Presence of clinically evident cirrhosis including: ascites requiring active diuretic&#xD;
             therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal&#xD;
             bleeding&#xD;
&#xD;
          2. Platelet count &lt; 50,000/mm3&#xD;
&#xD;
          3. Serum ALT level &gt; 10 times upper limit of normal&#xD;
&#xD;
          4. Alpha-fetoprotein level ≥ 200 ng/mL or alpha-fetoprotein level between 50-200 ng/mL in&#xD;
             association with liver ultrasound or other radiographic abnormality suspicious for&#xD;
             hepatic neoplasm&#xD;
&#xD;
          5. Serum creatinine level &gt; 1.6 mg/dL&#xD;
&#xD;
          6. Hematology outside of specified limits: neutrophil count &lt;1000/mm3, hemoglobin &lt;10&#xD;
             g/dL in males and &lt;9 g/dL in females&#xD;
&#xD;
          7. Unstable or uncontrolled thyroid disease&#xD;
&#xD;
          8. Treatment with any interferon-α or nucleoside/tide analog within the previous 4 weeks&#xD;
&#xD;
          9. Presence of clinically significant cryoglobulinemia (e.g., skin rash, arthritis, or&#xD;
             renal insufficiency due to cryoglobuliemia)&#xD;
&#xD;
         10. Presence or history of autoimmune hepatitis, alpha-1 anti-trypsin deficiency,&#xD;
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,&#xD;
             alcohol-related liver disease, primary biliary cirrhosis, or sclerosing cholangitis&#xD;
             (mild-to-moderate steatosis is acceptable)&#xD;
&#xD;
         11. Chronic hepatitis C infection&#xD;
&#xD;
         12. Hepatits Delta infection (HDV)&#xD;
&#xD;
         13. Known history of HIV infection or positive HIV antibody test by Western Blot (test&#xD;
             performed within 60 days of screening can be used to determine eligibility)&#xD;
&#xD;
         14. A disease known to cause significant alteration in immunologic function including&#xD;
             hematological malignancy or autoimmune disorder (e.g. rheumatoid arthritis, systemic&#xD;
             lupus erythematosis, autoimmune thyroid disease, leukemia, lymphoma, etc)&#xD;
&#xD;
         15. Concurrent therapy with immunosuppressive drugs or cytotoxic agents such as oral&#xD;
             prednisone, cyclosporine, azathioprine, or chemotherapeutic agent(s) (e.g.,&#xD;
             cyclophosphamide, methotrexate, or cancer chemotherapy) or radiation therapy&#xD;
&#xD;
         16. Behavior that suggests a significant risk of poor compliance including, but not&#xD;
             limited to:&#xD;
&#xD;
               1. Illicit drug abuse within the past 3 years&#xD;
&#xD;
               2. Current or history of alcohol abuse within the past 2 years&#xD;
&#xD;
         17. Prior treatment with IFN-γ 1b&#xD;
&#xD;
         18. History of unstable or deteriorating cardiac disease, including but not limited to:&#xD;
&#xD;
               1. Myocardial infarction, coronary artery bypass surgery, or angioplasty within the&#xD;
                  past 6 months&#xD;
&#xD;
               2. Congestive heart failure requiring hospitalization within the past 6 months&#xD;
&#xD;
               3. Uncontrolled arrhythmias&#xD;
&#xD;
               4. Transient ischemic attacks (TIAs)&#xD;
&#xD;
               5. Any cardiac condition that, in the opinion of the site PI, might be significantly&#xD;
                  exacerbated by flu-like symptoms associated with the administration of IFN γ 1b&#xD;
&#xD;
         19. Preexisting (within last two years) or active psychiatric condition including severe&#xD;
             depression, major psychoses, suicidal ideation or suicidal attempts&#xD;
&#xD;
         20. History of (within last two years) or current neurologic or psychiatric disorder that,&#xD;
             in the opinion of the site PI, might be exacerbated by flu-like symptoms associated&#xD;
             with the administration of IFN γ 1b. In addition, patients with the following&#xD;
             conditions should be excluded:&#xD;
&#xD;
               1. History of multiple sclerosis&#xD;
&#xD;
               2. Seizures within the past 2 years&#xD;
&#xD;
         21. Severe or poorly controlled diabetes&#xD;
&#xD;
         22. Pregnancy or lactation. Females of childbearing potential are required to have a&#xD;
             negative urine pregnancy test prior to treatment and must agree to practice abstinence&#xD;
             or prevent pregnancy by at least a barrier method of birth control for the duration of&#xD;
             the study&#xD;
&#xD;
         23. Hemoglobinopthies (e.g. thalassemia, sickle cell disease)&#xD;
&#xD;
         24. Any serious or chronic disease that, in the opinion of the Principal Investigator&#xD;
             (PI), may affect the assessment of safety or efficacy parameters. This includes, but&#xD;
             is not limited to, patients with malignancy who are receiving chemotherapy, chronic&#xD;
             obstructive pulmonary disease or asthma requiring maintenance oral steroids, or active&#xD;
             kidney disease&#xD;
&#xD;
         25. Any condition which, in the opinion of the site PI, is likely to result in the death&#xD;
             of the patient within the next year&#xD;
&#xD;
         26. Patients who, in the opinion of the site PI, are not suitable candidates for&#xD;
             enrollment or would not comply with the requirements of the study&#xD;
&#xD;
         27. Patients who have had a liver transplant&#xD;
&#xD;
         28. Patients who have Adefovir mutations on baseline tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron J Tong, Phd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HMRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntington Medical Research Institutes</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lori Tong, RN</last_name>
      <phone>626-397-5827</phone>
      <email>ltong@hmri.org</email>
    </contact>
    <investigator>
      <last_name>Myron J Tong, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hmri.org/</url>
    <description>Huntington Medical Research Institutes</description>
  </link>
  <link>
    <url>http://www.uclahealth.org/body.cfm?xyzpdqabc=0&amp;id=479&amp;action=detail&amp;ref=20715</url>
    <description>Myron J. Tong, PhD, MD</description>
  </link>
  <reference>
    <citation>Parvez MK, Sehgal D, Sarin SK, Basir SF, Jameel S. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol. 2006 May 21;12(19):3006-14.</citation>
    <PMID>16718779</PMID>
  </reference>
  <reference>
    <citation>Lau JY, Lai CL, Wu PC, Chung HT, Lok AS, Lin HJ. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J Med Virol. 1991 Jul;34(3):184-7.</citation>
    <PMID>1919540</PMID>
  </reference>
  <reference>
    <citation>Marcellin P, Loriot MA, Boyer N, Martinot-Peignoux M, Degott C, Degos F, Brandely M, Lenfant B, Benhamou JP. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology. 1990 Jul;12(1):155-8.</citation>
    <PMID>2115494</PMID>
  </reference>
  <results_reference>
    <citation>Narayan R, Buronfosse T, Schultz U, Chevallier-Gueyron P, Guerret S, Chevallier M, Saade F, Ndeboko B, Trepo C, Zoulim F, Cova L. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection. J Gen Virol. 2006 Nov;87(Pt 11):3225-3232. doi: 10.1099/vir.0.82170-0.</citation>
    <PMID>17030856</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J, Michalak TI. Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J Virol. 2006 Sep;80(17):8541-53.</citation>
    <PMID>16912304</PMID>
  </results_reference>
  <results_reference>
    <citation>Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9913-7. Epub 2005 Jul 1.</citation>
    <PMID>15994231</PMID>
  </results_reference>
  <results_reference>
    <citation>Park SG, Ryu HM, Lim SO, Kim YI, Hwang SB, Jung G. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology. 2005 Jun;128(7):2042-53.</citation>
    <PMID>15940636</PMID>
  </results_reference>
  <results_reference>
    <citation>Bissett J, Eisenberg M, Gregory P, Robinson WS, Merigan TC. Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: patients' tolerance and the effect on viral markers. J Infect Dis. 1988 May;157(5):1076-80.</citation>
    <PMID>3129521</PMID>
  </results_reference>
  <results_reference>
    <citation>Porres JC, Mora I, Gutiez J, Bartolome J, Quiroga JA, Bas C, Compernolle C, Ordi J, Chocarro A, Carreño V. Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study. Hepatogastroenterology. 1988 Feb;35(1):5-9.</citation>
    <PMID>2452123</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Bisceglie AM, Rustgi VK, Kassianides C, Lisker-Melman M, Park Y, Waggoner JG, Hoofnagle JH. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology. 1990 Feb;11(2):266-70.</citation>
    <PMID>2106474</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Myron Tong, PhD, MD</name_title>
    <organization>HMRI</organization>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Treatment</keyword>
  <keyword>Interferon-gamma</keyword>
  <keyword>combination</keyword>
  <keyword>Hepsera</keyword>
  <keyword>Actimmune</keyword>
  <keyword>HBV DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

